# Tenpoint Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tenpoint-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.tenpointtherapeutics.com
- Total disclosed funding: $155M
- Latest round: Series B (Jan 28, 2026)
- Investors on record: 13

## About

Based in Cambridge, UK, and founded in 2020 by Pete Coffey, Lyndon da Cruz, Deniz Dalkara, Olivier Goureau, Vanessa King, Thomas Reh, and José-Alain Sahel, Tenpoint Therapeutics Limited, a.k.a. Tenpoint Therapeutics operates as a biotech company that is developing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases. In January 2026, Tenpoint Therapeutics Limited raised USD 85 million in series B funding led by Janus Henderson Investors, with participation from EQT, Hillhouse Investment, British Business Bank, EQT Life Sciences, Sofinnova Partners, and F-Prime Capital. The round was part of a larger USD 235 million series B and venture debt funding. As of July 2023, Eddy Anglade is the CEO of the company.

The company is developing engineered cell-based therapeutics and in vivo reprogramming to reverse vision loss caused by the deterioration of functional tissue. Tenpoint Therapeutics also develops a regenerative medicine platform that helps replace cells destroyed by both age-related and inherited ocular diseases.

Tenpoint Therapeutics plans to use its proceeds from July 2023 funding to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.

## Funding rounds

- Series B, Jan 28, 2026, $85M — EQT, Sofinnova Partners, EQT Life Sciences, Qiming Venture Partners, Eight Roads Ventures, F-Prime Capital, British Business Bank, Janus Henderson Investors, Hillhouse Investment, AdBio Partners, Wille Finance
- Series A, Jul 12, 2023, $70M — Sofinnova Partners, Qiming Venture Partners, Eight Roads Ventures, F-Prime Capital, British Patient Capital, UCL Technology Fund

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- British Patient Capital — Series A
- UCL Technology Fund (https://capitalatlas.ai/funds/ucl-technology-fund) — Series A
- EQT (https://capitalatlas.ai/funds/eqt) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series B
- Janus Henderson Investors — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Series B
- Wille Finance — Series B